Resistance to Thyroid Hormone Alpha (RTHα) — Comprehensive Research Report

MONDO:0013757 | OMIM #614450 (listed as Hypothyroidism, Congenital, Nongoitrous, 6; CHNG6) | Gene: THRA (HGNC:11796, OMIM 190120, 17q21.1) | Orphanet: ORPHA 566231 | ICD-10: E07.8 (Other specified disorders of thyroid) | Category:* Mendelian, autosomal dominant

1. Disease Information

Overview. Resistance to thyroid hormone alpha (RTHα) is a rare autosomal dominant disorder caused by heterozygous, dominant-negative loss-of-function variants in THRA, the gene encoding thyroid hormone receptor alpha (TRα). Unlike classic "generalized" resistance to thyroid hormone (RTHβ, caused by THRB mutations), RTHα produces tissue-specific hypothyroidism confined largely to TRα1-expressing tissues (CNS, heart, gut, skeletal muscle, bone, erythroid precursors), while thyroid function tests remain near-normal because the hypothalamic-pituitary-thyroid feedback axis is governed by TRβ, which is unaffected. The first case was reported by Bochukova et al. in 2012 (PMID:22168587, N Engl J Med), describing a child with classic clinical features of hypothyroidism (growth retardation, developmental delay, skeletal dysplasia, severe constipation) but only borderline-abnormal thyroid function tests; whole-exome sequencing identified a de novo heterozygous nonsense variant (c.1207G>T, p.Glu403X) that "generated a mutant protein that inhibited wild-type receptor action in a dominant negative manner."

Only ~41 cases from ~28 families had been published in the literature as of the most recent comprehensive review period (2020–2024), making it an ultra-rare condition that is likely substantially underdiagnosed because, unlike RTHβ, standard thyroid function tests are not distinctive (van Mullem et al., Best Pract Res Clin Endocrinol Metab 2015, PMID:26303090).

Identifiers: - OMIM #614450 (CHNG6) - OMIM gene *190120 (THRA) - Orphanet ORPHA566231 - MONDO:0013757 - HGNC:11796 (THRA) - ICD-10: E07.8 - MeSH: THRA is indexed under "Thyroid Hormone Resistance Syndrome" (no disease-specific MeSH heading yet exists for RTHα specifically; it is typically captured under the RTH parent term)

Synonyms: Resistance to thyroid hormone due to a mutation in thyroid hormone receptor alpha; RTHα; THRA-related resistance to thyroid hormone; Congenital nongoitrous hypothyroidism 6 (CHNG6); Thyroid hormone resistance, alpha.

Evidence base: Nearly all data derive from individual case reports and small case series (aggregated in narrative and systematic reviews) rather than large epidemiologic cohorts or EHR-derived data, reflecting the condition's rarity (~41 published cases worldwide).

2. Etiology

Disease Causal Factors. RTHα is a purely genetic, monogenic disorder: heterozygous dominant-negative variants in THRA are both necessary and sufficient to cause the phenotype. There is no known environmental, infectious, or purely mechanistic (non-genetic) causal pathway.

Genetic risk factors: - Heterozygous THRA variants affecting the ligand-binding domain (LBD) (most reported variants) or, less commonly, variants affecting both TRα1 and the non-hormone-binding TRα2 isoform. - De novo occurrence is common; ~6 of the reported variants have been inherited from an affected parent, consistent with autosomal dominant transmission with full penetrance but markedly variable expressivity (van Mullem 2015, PMID:26303090; JCRPE clinical spectrum review 2021, PMC7947725). - Genotype severity correlates loosely with variant class: frameshift/premature-stop variants → more severe phenotype; missense variants → generally milder phenotype, though there is documented intrafamilial variability even with an identical missense variant (Nauwynck et al., Horm Res Paediatr 2026, PMID:42301959 — a mother and two daughters sharing c.1207G>A showed markedly different severity, "cannot be predicted by genotype alone").

Environmental risk factors: None established. There is no evidence that toxins, diet, occupational exposure, or perinatal factors modify risk of developing RTHα (it is not multifactorial).

Protective Factors: No protective genetic or environmental factors have been identified in the literature (the disease is fully penetrant for at least some phenotypic feature once the causal variant is present).

Gene-Environment Interactions: Not applicable/not reported; no GxE interaction data exist for this ultra-rare Mendelian disorder.

3. Phenotypes

The clinical picture is one of selective, tissue-specific hypothyroidism. Frequencies below are drawn from the JCRPE 2021 systematic clinical-spectrum review of published cases (PMC7947725) unless noted.

Neurodevelopmental / Behavioral

Delayed motor and speech milestones — ~85% (34/40 cases). HPO: Motor delay (HP:0001270), Delayed speech and language development (HP:0000750)
Dyspraxia / ataxic, broad-based gait, slow dysarthric speech — described as a major source of disability across ages. HPO: Dysdiadochokinesis/ Gait ataxia (HP:0002066), Dysarthria (HP:0001260)
Intellectual disability, variably reduced IQ — HPO: Intellectual disability (HP:0001249)
Autism spectrum features / ASD-associated variants — 6 THRA variants identified among 30 children screened in ASD cohorts (Kalikiri et al., Autism Res 2017, PMID:28856816). HPO: Autistic behavior (HP:0000729)
Seizures — reported in a minority of cases. HPO: Seizure (HP:0001250)

Growth / Skeletal

Short stature / growth retardation — ~60% (12/20 children), lowest height SD score −3.1. HPO: Short stature (HP:0004322)
Relative macrocephaly — ~70% (23/33). HPO: Macrocephaly (HP:0000256)
Delayed bone age / skeletal dysplasia / epiphyseal dysgenesis (childhood-specific; resolves in adulthood). HPO: Delayed skeletal maturation (HP:0002750), Epiphyseal dysplasia (HP:0002656)
Wormian bones (serpiginous cranial sutures, delayed fontanelle closure) — 32% (10/31). HPO: Wormian bones (HP:0002645)
Delayed tooth eruption — 44% (8/18 children). HPO: Delayed eruption of teeth (HP:0000684)
Short/broad facies, hypertelorism, flattened nose, macroglossia, thick lips (coarse facial gestalt) in ~one-third. HPO: Coarse facial features (HP:0000280), Macroglossia (HP:0000158)
Thickened calvarium / cortical hyperostosis / increased bone mineral density — characteristic in adults. HPO: Cranial hyperostosis (HP:0004437)
Short limbs, disproportionate short stature — reported in untreated adults (Bauer Westbye et al., J Endocr Soc 2023, PMID for bvad089 not captured in this pass)

Gastrointestinal

Chronic constipation — 84% (26/31) — one of the most consistent findings across the lifespan, attributed to decreased colonic peristalsis (documented by manometry). HPO: Constipation (HP:0002019)
Umbilical/inguinal hernias reported.

Dermatologic

Skin tags and moles (acrochordons), more prominent in adults — 21% (7/33). HPO: Skin tags (HP:0010701)
Rough, dry, thickened skin, particularly in children.

Hematologic

Mild, usually normocytic anemia — 77% (23/30); near-universal feature, unresponsive to hematinics, with normal iron/B12/folate (van Gucht et al., J Clin Endocrinol Metab 2017, PMID:28911146). HPO: Normocytic anemia (HP:0001923)

Cardiovascular / Metabolic

Bradycardia, abnormal sympathovagal balance, cardiac contractility indices in the hypothyroid range. HPO: Bradycardia (HP:0001662)
Rare cardiomyopathy (3 cases) and pericardial effusion (1 case) reported.
Low resting metabolic rate. HPO: Decreased basal metabolic rate (HP:0008977, if applicable — verify against enum)
Hepatic steatosis reported in adult cases (Nauwynck 2026).
Elevated LDL cholesterol. HPO: Hypercholesterolemia (HP:0003124)

Laboratory abnormalities

Elevated muscle creatine kinase — 73% (8/11 untreated children), range 218–981 U/L; proposed as a pediatric diagnostic biomarker.
Characteristic thyroid profile (see Section 4/biochemistry).

Phenotype characteristics: - Age of onset: Typically present from infancy/early childhood (growth faltering, developmental delay noted in first years of life); a subset of adult-onset features (tachycardia, hepatic steatosis, social/learning difficulties) may only become apparent or be recognized retrospectively in adulthood. - Severity: Highly variable — ranges from severely affected children (frameshift variants) to adults with mild learning difficulties who attended university untreated. - Progression: The "clinical picture or laboratory findings becom[e] less remarkable with age" in several domains (e.g., epiphyseal dysgenesis present in childhood is absent in adult imaging), but anemia, constipation, and cognitive effects can persist into adulthood. - Frequency: See percentages above (JCRPE 2021 review, n≈40 cases).

Quality-of-life impact: Motor dyspraxia, dysarthric speech, chronic constipation, fatigue, low mood, social dysfunction, and learning disabilities requiring educational support are reported to meaningfully affect daily functioning in both children (school performance) and untreated adults (concentration problems, excessive daytime sleepiness, social dysfunction) (Bauer Westbye/JES 2023 untreated-adult cohort).

4. Genetic/Molecular Information

Causal gene: THRA (HGNC:11796; OMIM *190120), chromosome 17q21.1.

Gene structure/isoforms: THRA produces two principal splice isoforms: - TRα1 — the biologically active, T3-binding nuclear receptor; high expression in CNS, myocardium, GI tract, skeletal muscle, bone. Molecular function: GO:0004887 (thyroid hormone receptor activity). - TRα2 — lacks a functional ligand-binding domain due to alternative C-terminal splicing; does not bind T3 but retains DNA-binding capacity and may act as an endogenous inhibitor of TRα1 signaling. RNA-seq data indicate TRα2 strongly predominates over TRα1 in the developing and adult human brain, a point relevant to interpreting variants that differentially affect the two isoforms.

Pathogenic variant spectrum (as of 2024 review, ~25 distinct variants across ~28 families): - Missense variants — most common class; generally milder phenotype; concentrated in the ligand-binding domain. - Examples with published functional characterization: - p.Glu403X (c.1207G>T) — the index Bochukova 2012 nonsense variant (PMID:22168587). - p.Ala263Val (A263V) — affects both TRα1 and TRα2; homologous to the RTHβ-causing THRB A317V variant; transcriptionally impaired at low T3 but function was restorable at higher hormone concentrations, "revers[ing] its dominant negative inhibitory activity" — a nuance relevant to high-dose therapy rationale. - p.Asn359Tyr (N359Y) — de novo, affects both isoforms; dominant-negative for TRα1, weaker dominant-negative effect for TRα2, especially when co-expressed with normal TRβ1. - p.Arg384Cys (R384C) — identified via whole-genome sequencing in an autism cohort; shown to be functionally deleterious in murine TRα1; transgenic mice exhibited aberrant GABAergic interneuron development and behavioral abnormalities that were reversible with thyroid hormone treatment initiated even in adulthood. - p.Asp268Asn — reported with early levothyroxine treatment and outcome data (J Pediatr Endocrinol Diabetes, recent case report). - p.Arg417Ter (c.1249C>T) and p.Glu173Gly (c.518A>G) — both logged in ClinVar under "Congenital nongoitrous hypothyroidism 6." - A synonymous substitution (c.1044G>T) was found in one autism cohort case, of uncertain pathogenicity for classic RTHα. - Frameshift variants — 3 reported variants affecting 4 cases, associated with the most severe phenotypes. - Nonsense/premature stop variants — 3 distinct variants.

Variant classification (ACMG/AMP): Per ClinVar, reported variants are generally classified Pathogenic/Likely Pathogenic for "Congenital nongoitrous hypothyroidism 6." Functional (in vitro transactivation/dominant-negative) assays are typically required to confirm pathogenicity of novel missense variants given the absence of a distinctive biochemical signature.

Variant origin: All reported RTHα cases are germline, heterozygous. No somatic THRA RTHα has been described (contrast with oncology literature in which THRA/TRα dysregulation — not classic RTHα missense variants — has been separately studied in some cancers; not relevant to this germline syndrome).

Allele frequency in population databases: THRA is under strong purifying selection for loss-of-function in gnomAD (constrained gene); reported RTHα pathogenic missense/truncating variants are essentially absent from population databases (gnomAD/ExAC/1000 Genomes), consistent with de novo origin and dominant pathogenicity — precise per-variant gnomAD frequencies were not captured in this pass and should be verified directly in gnomAD/ClinVar at curation time.

Functional consequence — mechanism: Dominant-negative loss of function. The mutant TRα1 protein retains DNA-binding and corepressor-binding capacity but fails to release corepressor complexes (NCoR1/SMRT + histone deacetylase, HDAC) upon T3 binding, resulting in "constitutive binding of mutant TR to corepressors, with failure of corepressor dissociation and coactivator recruitment following T3 occupancy," which "likely mediates dominant negative inhibition" over the co-expressed wild-type allele and, where relevant, TRβ (van Mullem 2015, PMC4559105).

Modifier genes: None formally established; authors speculate that "additional factors, possibly cofactor proteins" (e.g., corepressor/coactivator stoichiometry) contribute to the marked phenotypic variability seen even among carriers of an identical variant (intrafamilial variability, Nauwynck 2026).

Epigenetic information: No disease-specific DNA methylation/histone studies of patient tissue have been published; however, the core molecular mechanism is itself an epigenetic one at target-gene promoters — mutant TRα1 causes "constant HDAC-induced chromatin remodeling" that sustains transcriptional repression of T3 target genes even when hormone is present (mechanistic basis for HDAC-inhibitor experimental therapy, see Section 12).

Chromosomal abnormalities: No large structural/chromosomal (aneuploidy, translocation, CNV) etiology has been reported for RTHα; all reported cases are point variants (missense, nonsense, frameshift) within THRA.

5. Environmental Information

RTHα is a purely monogenic disorder. No environmental toxins, occupational exposures, lifestyle factors, or infectious agents have been implicated as causal or disease-modifying in the literature reviewed. This section is not applicable beyond noting that iodine status and maternal thyroid status during pregnancy are not reported to influence phenotype expression in THRA variant carriers (distinct from acquired thyroid disease).

6. Mechanism / Pathophysiology

Ordered causal chain

A heterozygous THRA variant (missense in the ligand-binding domain, or frameshift/nonsense) leads to expression of a mutant TRα1 protein (and, for variants upstream of the TRα2-specific exon, mutant TRα2) that retains DNA- and corepressor-binding activity but cannot release corepressor upon T3 binding.
This mutant receptor results in a dominant-negative effect: it competes with and suppresses the transcriptional activity of the co-expressed wild-type TRα1 allele (demonstrated mechanism) in TRα1-predominant tissues.
Constitutive corepressor (NCoR1/SMRT) and HDAC binding leads to persistent chromatin compaction at T3-responsive target gene promoters, i.e., a state of molecular/cellular hypothyroidism at the target-gene transcription level, despite near-normal circulating T3/T4 — this is the "tissue-specific hypothyroidism" hallmark of RTHα (inferred primarily from animal/in vitro reporter and chromatin studies, extrapolated to human disease).
Because the hypothalamic-pituitary-thyroid axis senses hormone levels predominantly via TRβ (which is unaffected), the pituitary/hypothalamus do not perceive tissue hypothyroidism, so TSH fails to rise compensatorily — explaining the near-normal-to-low-normal TSH and the diagnostic pitfall of relying on standard thyroid function tests.
In parallel, peripheral deiodinase handling is shifted (reduced TRα-mediated negative regulation of deiodinase activity is hypothesized), resulting in the characteristic biochemical signature: low/low-normal free T4, high/high-normal free T3, low/low-normal reverse T3, and an abnormally low FT4/FT3 ratio (directly demonstrated biochemically in patients; deiodinase-level mechanism is partly inferred).
In the CNS (where TRα1 — and especially TRα2 — predominates developmentally), impaired T3 target gene activation leads to abnormal neuronal/glial maturation, including — in the R384C mouse model — "aberrant development of GABAergic inhibitory interneurons," which manifests clinically as delayed motor/speech milestones, dyspraxia, ataxic gait, intellectual disability, and (in some cases) ASD features and seizures. This step is directly demonstrated in a murine model and inferred to extend to humans by phenotypic analogy.
In the growth plate/skeleton, dominant-negative TRα1 signaling causes delayed chondrocyte maturation and epiphyseal dysgenesis in childhood, resulting in short stature, delayed bone age, delayed tooth eruption, and the wormian-bone/cranial-suture phenotype; with skeletal maturation proceeding anomalously into adulthood as thickened calvarium/cortical hyperostosis and increased bone mineral density (demonstrated in both human imaging series and the Thra1^PV/+ mouse model).
In the gastrointestinal tract, impaired TRα1 signaling in enteric smooth muscle/neurons leads to decreased colonic peristalsis, manifesting as the near-universal chronic constipation.
In bone marrow erythroid progenitors, TRα1 dysfunction impairs the balance between proliferation and differentiation: patient-derived human erythroid progenitor cells (HEPs) show delayed spontaneous differentiation (~2 days later than controls), larger cell size, reduced glycophorin A (CD235a, a terminal differentiation marker) and increased c-Kit (CD117, a proliferation marker); exogenous T3 still accelerates differentiation in both control and patient cells, implying reduced (not absent) hormone sensitivity rather than complete unresponsiveness — resulting in the near-universal mild normocytic anemia (van Gucht 2017, PMID:28911146, direct human cell evidence).
In cardiac and skeletal muscle, TRα1 dysfunction results in reduced basal metabolic rate, bradycardia with abnormal sympathovagal balance, and elevated muscle creatine kinase — indices consistent with a tissue-level hypothyroid state that is relatively resistant to correction by standard-dose levothyroxine (see Treatment, Section 12), suggesting either incomplete T3 delivery/activation or genuinely reduced receptor responsiveness even at higher local hormone levels in these tissues.
Hepatic involvement (steatosis, elevated LDL/HDL ratio) has been reported in adult cases and is consistent with TRα1's role in lipid/metabolic regulation, though the liver is traditionally considered more TRβ-dominant — this cross-tissue effect is less well mechanistically characterized and should be considered a partially inferred branch of the pathway.

Molecular pathways

Canonical thyroid hormone receptor signaling (nuclear receptor transcriptional regulation): GO:0006355 (regulation of DNA-templated transcription) downstream of GO:0004887 (thyroid hormone receptor activity).
NCoR1/SMRT-HDAC corepressor pathway: central to the dominant-negative mechanism — GO:0035035 (histone acetyltransferase binding) / corepressor-related GO terms.

Cellular processes

Impaired erythroid progenitor proliferation/differentiation balance (GO:0030218, erythrocyte differentiation).
Impaired chondrocyte/osteoblast maturation in growth plate (relevant to skeletal dysplasia).
Altered GABAergic interneuron development in cortex (murine R384C model).

Protein dysfunction

Loss-of-function/dominant-negative missense or truncating changes in the TRα1 ligand-binding domain (helix 12 disruption in the mouse PV model prevents T3 binding/coactivator recruitment) or DNA-binding domain; UniProt P10827 (THRA/TRα). No protein aggregation/misfolding mechanism — this is a transcription-factor dominant-negative disorder, not a proteopathy.

Biochemical abnormalities

Characteristic pattern: low/low-normal FT4, high/high-normal FT3, low FT4/FT3 ratio, low/low-normal reverse T3, normal TSH, elevated CK (children especially), mild normocytic anemia, elevated LDL/total cholesterol, low/low-normal IGF-1, elevated IL-8 (pro-inflammatory).

Molecular profiling / advanced technologies

RNA-seq data show TRA2 isoform predominance over TRα1 in developing/adult human brain (relevant to interpreting CNS phenotype severity by variant location).
No large-scale patient transcriptomic, proteomic, or single-cell atlases specific to RTHα patient tissue were identified in this search pass; most molecular data derive from reporter-gene assays, patient-derived erythroid progenitor cultures, and murine/zebrafish models rather than from GEO/ArrayExpress patient cohorts.

Suggested ontology terms: - GO biological processes: GO:0006355 (regulation of transcription), GO:0030218 (erythrocyte differentiation), GO:0001501 (skeletal system development), GO:0007416 (synapse assembly, for GABAergic interneuron defect) - GO molecular function: GO:0004887 (thyroid hormone receptor activity) - Cell types (CL): CL:0000765 (erythroblast), CL:0000038 (erythroid progenitor cell), CL:0000138 (chondrocyte), CL:0000617 (GABAergic interneuron), CL:0000187 (myocyte), CL:0000216 (Sertoli cell — relevant to gonadal expression studies)

7. Anatomical Structures Affected

Organ level: - Primary: Central nervous system (brain), skeletal system (growth plate, calvarium, teeth), gastrointestinal tract (colon), hematopoietic system (bone marrow/erythroid lineage), cardiovascular system (heart). - Secondary: Liver (steatosis, lipid abnormalities reported in adults), skin (skin tags, dry/thickened skin). - Body systems: Endocrine, nervous, musculoskeletal, digestive, hematologic, cardiovascular.

Tissue/cell level: - Colonic smooth muscle/enteric neurons (constipation). - Growth-plate chondrocytes, osteoblasts/osteoclasts (skeletal dysplasia, increased cortical bone). - Erythroid progenitor cells in bone marrow (anemia). - Cortical GABAergic interneurons (murine model; presumptive human analog). - Cardiac myocytes (bradycardia, reduced contractility indices). - Skeletal muscle (elevated CK).

Subcellular level: - Nucleus — GO:0005634 (nucleus); TRα1 acts as a nuclear hormone receptor/transcription factor at target-gene promoters, with corepressor complexes recruiting HDAC to chromatin (GO:0000118, histone deacetylase complex).

Localization (UBERON): - UBERON:0000955 (brain), UBERON:0001968 (skeletal system), UBERON:0001155 (colon), UBERON:0002371 (bone marrow), UBERON:0000948 (heart), UBERON:0002107 (liver). - Lateralization: Not applicable; RTHα is a systemic, bilateral/symmetric disorder with no laterality pattern reported.

8. Temporal Development

Onset: Congenital/early-childhood onset for most features (growth faltering, developmental delay, delayed bone age typically recognized in infancy–early childhood); some features (hepatic steatosis, learning/social difficulties, tachycardia) are reported or first characterized in adulthood, either as persistence/evolution of the childhood phenotype or as later recognition in previously undiagnosed mild cases (e.g., the mother in the Nauwynck 2026 kindred).

Onset pattern: Insidious/chronic rather than acute — there is no described acute crisis presentation (contrast with, e.g., thyroid storm in Graves disease).

Progression: - Several skeletal features (epiphyseal dysgenesis) that are prominent in childhood are not present in adult imaging — i.e., some aspects of the phenotype attenuate with growth-plate closure. - Conversely, thickened calvarium/cortical hyperostosis and increased bone mineral density become more prominent in adults. - Anemia, constipation, and neurocognitive effects can persist through adulthood. - Overall the disease course is stable-to-slowly-evolving rather than progressive/degenerative; it is not described as a relapsing-remitting condition.

Disease duration: Chronic, lifelong — there is no spontaneous remission described, though the clinical and biochemical picture tends to become "less remarkable" with age in several (not all) domains.

Critical periods: Early childhood appears to be a critical window for neurodevelopmental intervention — case reports emphasize that "early treatment initiation yields more distinguishable developmental benefits," paralleling the R384C mouse data showing some interneuron/behavioral abnormalities are reversible with T3 treatment even in adulthood but presumably with better outcomes if treated early.

9. Inheritance and Population

Epidemiology: - Prevalence: Orphanet lists RTHα as prevalence <1 in 1,000,000 (ultra-rare). Approximately 41 cases across ~28 families have been published in the literature as of the most recent reviews (2021–2024), though the disorder is considered underdiagnosed given the non-distinctive standard thyroid panel. - Incidence: Not formally estimated in any population-based registry; no birth-prevalence studies exist.

Inheritance pattern: Autosomal dominant, with dominant-negative molecular mechanism. Most cases are de novo; at least 6 of the published variants have been transmitted from an affected parent, confirming vertical transmission is possible and documented.

Penetrance: Appears to be high/complete for at least some phenotypic feature (all reported heterozygous carriers show some abnormality), but with markedly incomplete and variable expressivity — severity is not predictable from genotype alone, as demonstrated by intrafamilial variability with an identical variant (Nauwynck 2026).

Expressivity: Highly variable, even within families carrying the identical missense variant — documented biochemical attenuation in an affected mother compared to her more severely affected daughters, and clinical heterogeneity (only one of two affected sisters had constipation and delayed dentition).

Genetic anticipation: Not reported/described for RTHα (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed, though it remains a theoretical consideration for any de novo dominant disorder when counseling families with an apparently de novo proband.

Founder effects: None reported; variants identified to date are private/family-specific rather than recurrent founder alleles in specific populations.

Consanguinity: Not implicated — consistent with a dominant (not recessive) mechanism.

Carrier frequency: Not applicable in the traditional sense (autosomal dominant, not a recessive carrier state); population databases (gnomAD) show the gene to be constrained, with disease-causing variants essentially absent from the general population.

Population demographics: - No specific ethnic or geographic enrichment has been established; cases have been reported from Europe (UK, Netherlands, Belgium, Scandinavia), the Middle East/North Africa (first MENA case report, PMC7897355), and elsewhere — consistent with a panethnic, privately-occurring de novo disorder rather than one with population-specific founder variants. - Sex ratio: Not clearly skewed in the literature; both males and females are affected (the described kindreds include affected mother-daughter pairs and isolated cases of both sexes). - Age distribution: Spans neonatal/infantile presentation through adulthood (documented adult cohort up to at least the 4th–5th decade, e.g., the untreated-adult J Endocr Soc cohort and 17-year follow-up case report).

10. Diagnostics

Clinical/laboratory tests: - Thyroid function panel (FT4, FT3, TSH, reverse T3) — the key diagnostic clue is low/low-normal FT4 + high/high-normal FT3 + normal TSH, yielding a low FT4/FT3 ratio and a high T3/rT3 ratio; reverse T3 is characteristically low/low-normal. Crucially, TSH is not elevated (distinguishing it from primary hypothyroidism and from RTHβ, where TSH is typically elevated/inappropriately normal with high T4). LOINC analytes: Free T4, Free T3, TSH, Reverse T3. - Creatine kinase (CK) — elevated in the majority of untreated children (73%, range 218–981 U/L); proposed as a pediatric screening/diagnostic biomarker, though normal in most untreated adults. - Complete blood count — mild normocytic (occasionally macrocytic) anemia with normal iron/B12/folate. - Lipid panel — elevated total/LDL cholesterol, elevated LDL/HDL ratio. - Imaging — skeletal survey/plain films for wormian bones, delayed bone age (childhood), thickened calvarium/cortical hyperostosis, increased bone mineral density (adulthood); dental films for delayed tooth eruption. - Colonic manometry has been used in at least one case to document decreased peristalsis underlying constipation.

Genetic testing: - Targeted THRA sequencing (single-gene test) is the most direct confirmatory test once RTHα is clinically suspected given a compatible biochemical pattern. Available through the NIH Genetic Testing Registry (GTR) for THRA (NCBI GTR Gene ID 7067). - Exome or genome sequencing has been the primary discovery route for nearly all reported cases (including the index Bochukova 2012 case and the R384C autism-cohort case), and remains appropriate given the nonspecific/attenuated biochemical phenotype that often does not trigger a targeted single-gene order. - Panel testing: RTHα should be considered in broader "thyroid hormone resistance" or "congenital hypothyroidism" NGS panels, and in intellectual-disability/neurodevelopmental gene panels given the overlap with developmental-delay presentations. - Chromosomal microarray/karyotype/FISH: Not relevant — RTHα is caused by point variants (missense/nonsense/frameshift), not copy-number or structural chromosomal changes; CMA/karyotype would be expected to be normal and is not a primary diagnostic tool for this condition.

Clinical criteria: No formal consensus diagnostic criteria (e.g., DSM/ICD-style) have been published; diagnosis rests on the combination of compatible phenotype + characteristic (if subtle) thyroid-hormone pattern + confirmatory THRA genetic testing.

Differential diagnosis: Primary congenital hypothyroidism, RTHβ (THRB-mediated generalized thyroid hormone resistance — distinguished by elevated TSH and high total T4/T3), other causes of short stature/developmental delay with skeletal dysplasia (e.g., skeletal dysplasia syndromes, other syndromic intellectual disability), and isolated chronic constipation of other etiology. Autism spectrum disorder of other genetic cause should also be considered, given the overlap with THRA variants found in ASD sequencing cohorts.

Screening: No newborn-screening program currently screens for RTHα (unlike primary congenital hypothyroidism, which is detected by TSH-based newborn screening — a modality that would miss RTHα because TSH is normal). Cascade family screening (biochemical + genetic) is recommended once a proband is identified, given documented intrafamilial transmission and variable expressivity (Nauwynck 2026 explicitly recommends "family-based genetic evaluation and cascade screening across lifespans").

11. Outcome/Prognosis

Survival/mortality: No excess mortality has been reported; RTHα is not described as life-limiting in published cases. No survival-rate or life-expectancy data exist (consistent with a non-lethal, chronic disorder), though systematic long-term outcome data are sparse given the small number of cases.

Morbidity/function: - Chronic constipation, dyspraxia/motor incoordination, dysarthric speech, variable intellectual disability, and social/learning difficulties are the dominant sources of disease-related disability. - Fertility appears unaffected: regular pregnancies have been reported in untreated affected females. - One untreated adult attended university despite mild childhood developmental delays, illustrating the wide severity range.

Disease course: - Complications include persistent anemia (often treatment-refractory), possible hepatic steatosis in adulthood, and — rarely — cardiomyopathy or pericardial effusion. - Recovery/improvement potential with treatment is domain-specific (see Section 12): neurodevelopmental/behavioral and GI symptoms respond better than growth, cardiac, and hematologic parameters.

Prognostic factors: - Variant type (frameshift/truncating → more severe) is the most consistently cited prognostic factor. - Age at treatment initiation — earlier initiation of levothyroxine is associated with more distinguishable developmental benefit. - Tissue-specific TRα expression and (speculative) cofactor/corepressor stoichiometry differences likely contribute to the unexplained intrafamilial variability.

Prognostic biomarkers: Elevated CK in childhood has been proposed as a biomarker correlating with disease activity/severity, though this is not validated as a formal prognostic tool; no molecular prognostic biomarker panel currently exists.

12. Treatment

Pharmacotherapy — Levothyroxine (LT4): - LT4 has been "the first choice to date" and is the mainstay of treatment, typically dosed above what would be used for standard primary hypothyroidism to attempt to overcome TRα resistance in affected tissues, producing a biochemical pattern resembling central-hypothyroidism treatment (rise in FT3/FT4 with TSH suppression). NCIT term: NCIT:C15986 (Pharmacotherapy); therapeutic agent — CHEBI levothyroxine, or NCIT drug term for Levothyroxine. - Clinical benefits documented: improvement in constipation (majority of cases), motor coordination, alertness, school performance, concentration, motivation, hypotonia, accelerated neuromotor development in children treated early, improved dyspraxia and social interaction in adults, reduction in elevated LDL cholesterol and muscle CK, and increases in IGF-1 and SHBG. - Limited/no response: Anemia is largely unresponsive to LT4. Linear growth shows only limited benefit. Cardiac parameters (heart rate, contractility indices) and resting energy expenditure/muscle CK are comparatively poorly responsive relative to the degree of biochemical (FT3/FT4) correction achieved — i.e., tissues show differential sensitivity to exogenous hormone even at supraphysiologic FT3 exposure. - Safety concern: Because TSH readily suppresses with LT4 while some TRα-dependent tissues remain resistant, patients can develop supraphysiologic FT3 levels — raising concern for "unwanted toxicities in normal TRβ-containing tissues" (e.g., theoretical cardiac/bone risk from chronic T3 excess in tissues where TRβ signaling is intact), a safety tension unique to treating a receptor-specific resistance syndrome with a non-selective hormone. - Liothyronine (T3): used in at least one atypical case, associated with cardiac/metabolic response; generally considered a second-line or individualized option given the already-elevated endogenous FT3 in most patients.

Pharmacogenomics: No THRA-specific pharmacogenomic (drug-metabolism) data were identified; this is a receptor-resistance disorder rather than a drug-metabolism disorder, so conventional PharmGKB-style variant-drug interaction data are not applicable in the usual sense.

Advanced therapeutics (experimental / preclinical): - TRα1-selective thyromimetics are proposed as the ideal future approach — compounds that would selectively activate residual normal TRα1 (or partially-functional mutant TRα1) in TRα-predominant tissues while sparing TRβ-dominant tissues from toxicity. None are yet in human trials for RTHα specifically; existing thyromimetic development (e.g., sobetirome, a TRβ-selective agonist developed for dyslipidemia/demyelinating disease, and resmetirom, approved for MASH) is TRβ-selective and thus not directly applicable/may be the wrong receptor target for RTHα. - Corepressor/HDAC-pathway targeting: Because the core molecular lesion is failure to release the NCoR/SMRT-HDAC corepressor complex, genetic disruption of NCoR-TR interaction or pharmacologic HDAC inhibition has been tested in the murine Thra1^PV/+ model with conflicting results across studies — an earlier study (Subramanian et al., Hum Mol Genet 2014, PMID:24381310) reported the HDAC inhibitor SAHA (vorinostat) improved growth and bone development in Thra1^PV/+ mice, while a later, more detailed skeletal-phenotyping study (Freudenthal et al., Thyroid 2019, PMC6533791) found SAHA had "no beneficial or detrimental effects on bone structure, mineralization, or strength" and concluded SAHA treatment was "unlikely to improve the skeletal manifestations of RTHα" — an explicit model-divergence worth flagging in any curated entry (conflicting computational/animal-model evidence on the same pharmacologic strategy). - Gene therapy / RNA-based therapy / cell therapy / immunotherapy: None reported or in development specific to RTHα (not relevant given the dominant-negative, gain-of-repressive-function mechanism, which would require allele-selective silencing rather than simple gene replacement — no such approach has been published for this condition).

Surgical/interventional: Not applicable — RTHα has no surgical treatment indication.

Supportive/rehabilitative: - Physical/occupational/speech therapy for dyspraxia, gross/fine motor incoordination, and dysarthric speech (NCIT:C15302 Physical Therapy). - Dietary/laxative management of chronic constipation. - Educational support for learning disabilities.

Experimental treatment registries: A deep genotyping/phenotyping patient registry, DEEPTYPE — "Register for Patients With Thyroid Hormone Resistance" (ClinicalTrials.gov NCT06566066), is an active, ongoing registry study (estimated primary completion ~2029) intended to better characterize thyroid hormone resistance syndromes (including presumably RTHα) — full protocol detail (sponsor, eligibility specifics) could not be retrieved in this research pass and should be verified directly on ClinicalTrials.gov before citing as evidence.

Treatment outcomes / adverse events: No FAERS-level pharmacovigilance data exist specific to LT4 use in RTHα (too rare); adverse-event concerns are inferred mechanistically (supraphysiologic FT3 exposure risk) rather than empirically demonstrated in large cohorts.

Treatment algorithm / personalized medicine: No formal clinical practice guideline exists; management is individualized, typically involving endocrinology-led titration of LT4 (sometimes supplemented with T3) guided by clinical response (growth, constipation, developmental progress) more than by strict biochemical targets, given the blunted/variable biochemical-to-clinical correlation described above.

13. Prevention

Because RTHα is caused by de novo or inherited dominant germline variants with no known environmental trigger, classic primary prevention (risk-factor modification, vaccination) and public-health/environmental interventions are not applicable.

Secondary prevention (early detection): Cascade genetic/biochemical screening of first-degree relatives of an identified proband is explicitly recommended in the literature (Nauwynck 2026) given documented familial transmission and variable expressivity — early identification in an asymptomatic/mildly symptomatic relative could in principle allow earlier initiation of supportive and thyroid-hormone interventions, though no formal screening protocol or outcome data for this strategy were identified.
Genetic counseling: Recommended for identified families — autosomal dominant inheritance with a ~50% transmission risk to offspring of an affected parent, but with emphasis on the unpredictability of phenotypic severity (NCIT:C15240, Genetic Counseling).
Prenatal/preimplantation genetic testing: Not specifically reported as used for RTHα in the literature reviewed, though it would be technically available once a familial pathogenic variant is known (standard for autosomal dominant single-gene disorders).
Newborn screening: Current TSH-based newborn congenital-hypothyroidism screening programs will not detect RTHα (TSH is normal), which is explicitly identified in the literature as a major reason for underdiagnosis; no RTHα-specific newborn screening assay currently exists.
Prophylaxis: Not applicable (no known preventable trigger).

14. Other Species / Natural Disease

Taxonomy: No naturally-occurring (spontaneous) RTHα has been reported in companion animals or wildlife (e.g., no OMIA entry for spontaneous THRA RTHα disease was identified in this pass). All non-human data derive from engineered/induced genetic models (see Section 15), not naturally occurring veterinary disease.

Gene orthology: Thra is highly conserved; mouse Thra (MGI:98743) and zebrafish thraa/thrab (duplicated paralogs, reflecting teleost genome duplication) are the principal orthologs exploited for modeling.

Comparative biology: The corepressor-release mechanism of TRα1 dominant-negative action is conserved from fish to mammals, supporting cross-species extrapolation of mechanistic findings, though the existence of a duplicated thra locus in zebrafish (thraa/thrab) is a structural divergence from the single-copy human/mouse gene that must be considered when interpreting zebrafish dominant-negative results (a single thra paralog's mutation may be partially compensated by the other).

Zoonotic/transmission relevance: Not applicable — this is a non-infectious, non-transmissible genetic disorder.

15. Model Organisms

Mouse models: - Thra1^PV/+ knock-in mouse — the principal, most extensively characterized model. The PV mutation is a C-insertion causing a frameshift that disrupts helix 12 of the TRα1 ligand-binding domain, abolishing T3 binding and coactivator recruitment while preserving (indeed enhancing) corepressor binding — producing a potent dominant-negative receptor closely analogous to human disease-causing truncating variants. - Phenotype recapitulation: Near-normal standard thyroid function tests (mirroring the human diagnostic challenge), growth retardation, delayed bone development, reduced fat mass and liver size, abnormal (grossly abnormal) bone morphology with paradoxically preserved/high bone mass and normal bone strength in adult females, short stature, and short limbs — closely recapitulating the human skeletal phenotype. - Erythroid phenotype: Thra1^PV/+ mice show abnormal red blood cell indices similar to patients, with decreased expression of the erythroid master regulator Gata-1 and its target genes in bone marrow, proposed as the mechanism by which mutant TRα1PV impairs erythropoiesis (mouse-model mechanistic claim — note this Gata1-repression mechanism was not corroborated in the human erythroid-progenitor study by van Gucht et al. 2017, which instead emphasized a proliferation/differentiation-balance defect without mention of GATA1 — a human/model divergence worth flagging when curating the erythropoiesis mechanism). - Corepressor rescue experiment: Introducing a mutation in NCoR1 that abrogates its interaction with TR, in the Thra1^PV/+ background, ameliorates growth and bone-development phenotypic abnormalities — direct genetic evidence for the corepressor-centered dominant-negative mechanism. - Pharmacologic rescue (HDAC inhibition): Conflicting results between two independent studies (Subramanian 2014 positive; Freudenthal 2019 negative for skeletal endpoints specifically) — see Section 12 for detail on this model divergence. - Behavioral/CNS models: Neuronal-specific expression of a dominant-negative TRα mutant alters mouse behavior (anxiety/depressive-like behaviors noted); relevant to the human neurocognitive/psychiatric phenotype but an extrapolation from a targeted-expression model rather than the global knock-in. - Gonadal expression models: Expression of dominant-negative TRα1 in Leydig and Sertoli cells demonstrated no additional reproductive defect compared with Sertoli-cell-only expression, suggesting TRα1 dysfunction in Leydig cells does not compound the male reproductive phenotype beyond the Sertoli-cell effect — consistent with the clinical observation that fertility is largely preserved in human RTHα. - Limitations of the mouse model: No fully "amendable" (i.e., easily genetically/embryologically manipulable) mouse model exists for studying very early embryonic/developmental consequences of TRα1 dominant-negative mutations — this gap motivated development of the zebrafish models below.

Zebrafish models: - CRISPR/Cas9-generated dominant-negative mutations in the duplicated zebrafish thra paralogs (thraa, thrab) allow study of THRA variant consequences during early embryonic development, which is experimentally inaccessible in mammalian models. - Human THRA variants have been functionally tested in vivo by expression in zebrafish, demonstrating "in vivo functional consequences of human THRA variants" and validating zebrafish as a variant-classification/functional-assay platform. - A specific thraa mutant line carrying an 8-bp insertion (truncating Thraa, impairing TH signaling) has been separately characterized for its effect on cardiac regeneration, finding that thraa loss-of-function enhances zebrafish heart regenerative capacity through metabolic/hypoxic regulation — an intriguing but mechanistically distinct line of investigation (cardiac regeneration biology) rather than a direct RTHα disease model, and should not be conflated with the human cardiac hypothyroid phenotype (bradycardia/reduced contractility) without further validation. - THRA mutant zebrafish also show heart defects, directly supporting a TRα-dependent cardiac developmental role relevant to human cardiac findings.

Cellular/in vitro models: - Patient-derived human erythroid progenitor cells (HEPs) cultured from peripheral blood of RTHα patients — used to directly demonstrate the human erythropoiesis defect (van Gucht 2017), representing a direct human cellular model rather than an animal surrogate. - Reporter-gene transactivation assays (transfected cell lines expressing mutant TRα1/TRα2 constructs) — the standard functional-characterization approach for essentially every novel missense variant reported (e.g., A263V, N359Y, R384C functional studies cited above).

Resources: MGI (mouse Thra models), ZFIN (zebrafish thraa/thrab lines); no dedicated IMPC/KOMP conditional RTHα allele set was identified in this pass beyond the PV knock-in lineage.

Summary of Key Evidence Gaps (for curation awareness)

Precise per-variant gnomAD/ClinVar allele-frequency and ACMG classification detail was not individually verified for every reported variant in this pass and should be confirmed directly against ClinVar/gnomAD before binding specific variant records.
The erythropoiesis mechanism shows a model-organism/human divergence: mouse data implicate Gata1 repression; the direct human progenitor-cell study instead emphasizes a proliferation/differentiation kinetic defect without invoking Gata1 — this is a genuine discrepancy, not merely a gap, and should be modeled as such (e.g., via divergences/HUMAN_MODEL_MISMATCH framing) rather than harmonized.
The HDAC-inhibitor (SAHA) therapeutic strategy has directly conflicting preclinical results (positive in Subramanian 2014; negative on skeletal endpoints in Freudenthal 2019) and should not be curated as a settled positive therapeutic lead.
Exact PMIDs for the JCRPE clinical-spectrum review and the J Endocr Soc untreated-adult cohort paper were not definitively captured during this search pass (PMC identifiers were obtained; PMID lookup should be completed at curation time).
The DEEPTYPE registry (NCT06566066) protocol detail (explicit RTHα inclusion, sponsor) could not be retrieved and should be verified directly on ClinicalTrials.gov.

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Table (click to expand)

Outcome	Count
References checked	20
Resolved	20
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	20
On topic	18
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Table (click to expand)

Outcome	Count
Terms checked	48
Resolved	44
Unresolved (possible confabulation)	1
Obsolete	1
Unverifiable	2
Terms whose name was checked	41
Terms named correctly	32
Terms named as a different term	6
Terms whose name is worth a second look	3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

HP:0010701 (1 mention) - the report calls it "Skin tags"; HP calls it Abnormal circulating immunoglobulin concentration
HP:0001923 (1 mention) - the report calls it "Normocytic anemia"; HP calls it Reticulocytosis
GO:0004887 (3 mentions) - the report calls it "thyroid hormone receptor activity"; GO calls it GO_0004887
GO:0007416 (1 mention) - the report calls it "synapse assembly, for GABAergic interneuron defect"; GO calls it synapse assembly
CL:0000216 (1 mention) - the report calls it "Sertoli cell — relevant to gonadal expression studies"; CL calls it Sertoli cell
UBERON:0001968 (1 mention) - the report calls it "skeletal system"; UBERON calls it semen

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

HP:0008977 (1 mention) - HP does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0004887 (GO_0004887) (3 mentions) - replaced by GO:0004879

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

GO:0006355 (2 mentions) - the report calls it "regulation of DNA-templated transcription", "regulation of transcription"; GO calls it regulation of DNA-templated transcription
CL:0000617 (1 mention) - the report calls it "GABAergic interneuron"; CL calls it GABAergic neuron
CL:0000187 (1 mention) - the report calls it "myocyte"; CL calls it muscle cell, and lists "myocyte" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

GO:0006355 - called "regulation of DNA-templated transcription", "regulation of transcription"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: MGI.